ALK-Abelló
ALK-Abelló A/S (Nasdaq Copenhagen: ALK B), also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy (AIT) products for the prevention and treatment of allergy. It is one of the world's largest makers of allergy immunotherapy products (also known as ‘allergy vaccines’) with 67% of its revenue coming from sales in Europe.
| Company type | Aktieselskab |
|---|---|
Traded as | Nasdaq Copenhagen: ALK B |
| Industry | Pharmaceuticals |
| Founded | 1923 Copenhagen |
| Founder | Kaj Hedemann Baagøe Peter Barfod |
| Headquarters | Hørsholm, Denmark |
Key people | Anders Hedegaard (Chairman) Peter Halling (CEO) |
| Products | Acarizax, Grazax, SlitOneUltra, Alutard SQ, Jext |
| Revenue | DKK 4.824 billion (2023) |
Number of employees | 2,900 (2023) |
| Website | www.alk.net |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.